A surprising complete response to cadonilimab in a primary metastatic cervical cancer: a case report
The outcome of patients with recurrent/metastatic cervical cancer (R/M CC) is poor, with a 5-year survival rate of only 10%–20%. Recent advances in immunotherapy renewed its interest in R/M CC treatment. It has been suggested that cadonilimab, a novel bispecific antibody targeting programmed death 1...
Saved in:
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2024-11-01
|
| Series: | Frontiers in Immunology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2024.1494138/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1846156370426986496 |
|---|---|
| author | Haijuan Yu Jie Lin Jian Chen Lijun Chen Jianping Zou Bin Liu Dan Hu Youping Xiao Linhao Yu Yang Sun |
| author_facet | Haijuan Yu Jie Lin Jian Chen Lijun Chen Jianping Zou Bin Liu Dan Hu Youping Xiao Linhao Yu Yang Sun |
| author_sort | Haijuan Yu |
| collection | DOAJ |
| description | The outcome of patients with recurrent/metastatic cervical cancer (R/M CC) is poor, with a 5-year survival rate of only 10%–20%. Recent advances in immunotherapy renewed its interest in R/M CC treatment. It has been suggested that cadonilimab, a novel bispecific antibody targeting programmed death 1 (PD-1) and cytotoxic T-lymphocyte antigen-4 (CTLA-4), significantly improved the survival outcomes of the R/M CC. In the present study, we reported a programmed death ligand 1 (PD-L1) and human epidermal growth factor receptor 2 (HER-2) positive CC case at stage IV who was treated with cadonilimab and achieved a surprising radiographic complete response (CR) for 10 months, even in the PD-L1 negative metastatic site. Demographic, clinical, histopathological, laboratory, treatment regime and imaging data were recorded. Unfortunately, the patient progressed rapidly during maintenance therapy when cadonilimab was replaced by sintilimab, the monoclonal antibody against PD-1, indicating the more powerful anti-tumor activity of dual blockade immunotherapy. To conclude, cadonilimab offers a promising and effective therapeutic approach for R/M CC. Notably, HER-2 is also expected to be a new reference target for cadonilimab therapy. |
| format | Article |
| id | doaj-art-2f212fd5fcb14ab2bc8d0b471b0fe99a |
| institution | Kabale University |
| issn | 1664-3224 |
| language | English |
| publishDate | 2024-11-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Immunology |
| spelling | doaj-art-2f212fd5fcb14ab2bc8d0b471b0fe99a2024-11-26T06:26:12ZengFrontiers Media S.A.Frontiers in Immunology1664-32242024-11-011510.3389/fimmu.2024.14941381494138A surprising complete response to cadonilimab in a primary metastatic cervical cancer: a case reportHaijuan Yu0Jie Lin1Jian Chen2Lijun Chen3Jianping Zou4Bin Liu5Dan Hu6Youping Xiao7Linhao Yu8Yang Sun9Department of Gynecology, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou, Fujian, ChinaDepartment of Gynecology, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou, Fujian, ChinaDepartment of Gynecology, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou, Fujian, ChinaDepartment of Gynecology, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou, Fujian, ChinaDepartment of Gynecology, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou, Fujian, ChinaDepartment of Gynecology, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou, Fujian, ChinaDepartment of Pathology, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou, Fujian, ChinaDepartment of Radiology, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou, Fujian, ChinaDepartment of Pathology, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou, Fujian, ChinaDepartment of Gynecology, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou, Fujian, ChinaThe outcome of patients with recurrent/metastatic cervical cancer (R/M CC) is poor, with a 5-year survival rate of only 10%–20%. Recent advances in immunotherapy renewed its interest in R/M CC treatment. It has been suggested that cadonilimab, a novel bispecific antibody targeting programmed death 1 (PD-1) and cytotoxic T-lymphocyte antigen-4 (CTLA-4), significantly improved the survival outcomes of the R/M CC. In the present study, we reported a programmed death ligand 1 (PD-L1) and human epidermal growth factor receptor 2 (HER-2) positive CC case at stage IV who was treated with cadonilimab and achieved a surprising radiographic complete response (CR) for 10 months, even in the PD-L1 negative metastatic site. Demographic, clinical, histopathological, laboratory, treatment regime and imaging data were recorded. Unfortunately, the patient progressed rapidly during maintenance therapy when cadonilimab was replaced by sintilimab, the monoclonal antibody against PD-1, indicating the more powerful anti-tumor activity of dual blockade immunotherapy. To conclude, cadonilimab offers a promising and effective therapeutic approach for R/M CC. Notably, HER-2 is also expected to be a new reference target for cadonilimab therapy.https://www.frontiersin.org/articles/10.3389/fimmu.2024.1494138/fullcadonilimabrecurrent and/or metastatic cervical cancercomplete responseHER-2case report |
| spellingShingle | Haijuan Yu Jie Lin Jian Chen Lijun Chen Jianping Zou Bin Liu Dan Hu Youping Xiao Linhao Yu Yang Sun A surprising complete response to cadonilimab in a primary metastatic cervical cancer: a case report Frontiers in Immunology cadonilimab recurrent and/or metastatic cervical cancer complete response HER-2 case report |
| title | A surprising complete response to cadonilimab in a primary metastatic cervical cancer: a case report |
| title_full | A surprising complete response to cadonilimab in a primary metastatic cervical cancer: a case report |
| title_fullStr | A surprising complete response to cadonilimab in a primary metastatic cervical cancer: a case report |
| title_full_unstemmed | A surprising complete response to cadonilimab in a primary metastatic cervical cancer: a case report |
| title_short | A surprising complete response to cadonilimab in a primary metastatic cervical cancer: a case report |
| title_sort | surprising complete response to cadonilimab in a primary metastatic cervical cancer a case report |
| topic | cadonilimab recurrent and/or metastatic cervical cancer complete response HER-2 case report |
| url | https://www.frontiersin.org/articles/10.3389/fimmu.2024.1494138/full |
| work_keys_str_mv | AT haijuanyu asurprisingcompleteresponsetocadonilimabinaprimarymetastaticcervicalcanceracasereport AT jielin asurprisingcompleteresponsetocadonilimabinaprimarymetastaticcervicalcanceracasereport AT jianchen asurprisingcompleteresponsetocadonilimabinaprimarymetastaticcervicalcanceracasereport AT lijunchen asurprisingcompleteresponsetocadonilimabinaprimarymetastaticcervicalcanceracasereport AT jianpingzou asurprisingcompleteresponsetocadonilimabinaprimarymetastaticcervicalcanceracasereport AT binliu asurprisingcompleteresponsetocadonilimabinaprimarymetastaticcervicalcanceracasereport AT danhu asurprisingcompleteresponsetocadonilimabinaprimarymetastaticcervicalcanceracasereport AT youpingxiao asurprisingcompleteresponsetocadonilimabinaprimarymetastaticcervicalcanceracasereport AT linhaoyu asurprisingcompleteresponsetocadonilimabinaprimarymetastaticcervicalcanceracasereport AT yangsun asurprisingcompleteresponsetocadonilimabinaprimarymetastaticcervicalcanceracasereport AT haijuanyu surprisingcompleteresponsetocadonilimabinaprimarymetastaticcervicalcanceracasereport AT jielin surprisingcompleteresponsetocadonilimabinaprimarymetastaticcervicalcanceracasereport AT jianchen surprisingcompleteresponsetocadonilimabinaprimarymetastaticcervicalcanceracasereport AT lijunchen surprisingcompleteresponsetocadonilimabinaprimarymetastaticcervicalcanceracasereport AT jianpingzou surprisingcompleteresponsetocadonilimabinaprimarymetastaticcervicalcanceracasereport AT binliu surprisingcompleteresponsetocadonilimabinaprimarymetastaticcervicalcanceracasereport AT danhu surprisingcompleteresponsetocadonilimabinaprimarymetastaticcervicalcanceracasereport AT youpingxiao surprisingcompleteresponsetocadonilimabinaprimarymetastaticcervicalcanceracasereport AT linhaoyu surprisingcompleteresponsetocadonilimabinaprimarymetastaticcervicalcanceracasereport AT yangsun surprisingcompleteresponsetocadonilimabinaprimarymetastaticcervicalcanceracasereport |